A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
about
Antiviral perspectives for chikungunya virusPrime-boost immunization strategies against Chikungunya virusDevelopment of Neutralization Assay Using an eGFP Chikungunya VirusChikungunya vaccines in developmentThe evolution of poxvirus vaccinesA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenRNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammationDevelopment of Vaccines for Chikungunya Fever.Strategies towards universal pandemic influenza vaccines.A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in miceA novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizationsEnhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line.Oncolytic Poxviruses.Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesEnhancing poxvirus vectors vaccine immunogenicity.Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.Protective and Pathogenic Responses to Chikungunya Virus Infection.Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies.Chikungunya fever: an emerging viral infection threatening North America and Europe.Chikungunya Virus Vaccines: Viral Vector-Based Approaches.Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein.Poxvirus Host Range Genes and Virus-Host Spectrum: A Critical Review.DNA Vaccines: Recent Developments and the Future.Vaccine and Therapeutic Options To Control Chikungunya Virus.Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boostCellular and Molecular Immune Response to Chikungunya Virus Infection
P2860
Q21284682-3FCAFA60-D5B5-479A-B839-DB54B787CE88Q24701774-729BB2D0-FB69-4304-81C4-9C8351121AAFQ26314416-D74D16F9-55DC-4C1D-88AF-E57D22CAC586Q26700081-05D2F7E6-8ADE-4550-9DD9-2743CFAFC39DQ26995905-060CABD6-83A0-41A3-856A-A2C7B1F6F1F0Q27302081-997B52CD-A061-45B7-873D-AD544ADB6B1CQ28804081-98E94EA5-D5CE-44FF-8AFB-CA445E19A164Q30240191-0215EC76-5760-410D-9A70-4DDA50607ECFQ30382226-9687F52A-6547-4D11-9170-A40913737334Q30938741-9D915398-F791-4574-9D7F-081C5FB261F8Q33945612-2E99E20A-5775-4F36-926E-45229DBEBA08Q34593874-25003D5C-B009-4211-9A3C-E1467D0D8DE9Q35142715-D778814F-567C-429F-BAE8-5DDD9184E8BFQ35234349-8C88BEF8-441A-47DD-92CE-E5AD5A805E1AQ35238179-A6C53F75-972A-42D0-B595-8E29B84F63A9Q35928588-A99B931D-F2BF-4E57-88F3-59A75B95FF13Q36978452-9C6C903B-1E6B-48E6-AFF6-CD46D38754E2Q37711813-4B12271B-32E3-4F92-BE9F-DC83C49F9E1AQ38586243-778AF85B-92A8-4E64-913B-C02C429A140DQ38666344-C236CFAA-3EB0-4B76-A50F-3D37B7E7B615Q38964360-C38E930B-774D-48B3-B0AF-DE2A10C872B9Q39128566-0DF42120-FA3D-4CD0-9DA2-9D83FA751405Q40077678-8E82860C-3704-4973-A41A-69DCF5116B20Q40113025-7741A4CB-7C1D-46EF-91CC-1922A811DFC8Q40117821-A7F7B7C9-4F9E-42A4-9106-C4B3EC0C01A7Q40290590-B7D5505A-7236-4C7A-8860-1D5BB1DA9C31Q44169408-3952E066-2299-4648-8C3A-B95C7F3CBC13Q45325191-18AFBB7F-D036-4883-B2FC-E93852D1D86EQ45892465-75DDEEFE-F5D7-4887-BFA0-4902F9AEA3D0Q47566099-5AAB2656-DAD4-43EF-9B59-3839ACA4E3DBQ50329180-BEF9414D-3B27-4AFD-8BC4-ECC2B2C2DABBQ51784219-FF7E23EF-6D09-4791-A793-41AB67AEF474Q56973287-2E9F17A2-DF99-43AE-AD26-38FF6C6351FCQ58575620-43F471BE-F550-4054-8EDC-3D9658A697D3
P2860
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel poxvirus-based vaccine ...... against chikungunya infection.
@en
A novel poxvirus-based vaccine ...... against chikungunya infection.
@nl
type
label
A novel poxvirus-based vaccine ...... against chikungunya infection.
@en
A novel poxvirus-based vaccine ...... against chikungunya infection.
@nl
prefLabel
A novel poxvirus-based vaccine ...... against chikungunya infection.
@en
A novel poxvirus-based vaccine ...... against chikungunya infection.
@nl
P2093
P2860
P50
P356
P1433
P1476
A novel poxvirus-based vaccine ...... against chikungunya infection
@en
P2093
Beate Mareike Kümmerer
Carlos Óscar S Sorzano
David Hallengärd
Victoria Cepeda
P2860
P304
P356
10.1128/JVI.03418-13
P407
P5008
P577
2014-01-08T00:00:00Z